UK markets closed

Photocure ASA (0IMT.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
62.10-0.50 (-0.80%)
At close: 03:01PM BST
Full screen
Previous close62.60
Bid0.00 x 0
Ask0.00 x 0
Day's range62.00 - 62.30
52-week range40.85 - 71.90
Avg. volume2,783
Market cap1.214B
Beta (5Y monthly)0.91
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

    Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has commenced activities to support a new initiative enabling U.S. Hospitals and Clinics to offer blue light cystoscopy (BLC®) using a mobile capital equipment model. The initiative is aligned with a recently executed agreement between Karl Storz and ForTec Medical, aimed at providing on-demand Saphira™ BLC equipment to hospitals in the U.S. leveraging ForTec's utilization-driven mobile equipment business model.

  • PR Newswire

    Photocure ASA - Annual general meeting held

    Photocure ASA (OSE: PHO), held its annual general meeting on 23 May 2024 at 17:00 hours (CEST).

  • PR Newswire

    Photocure ASA: Results for the first quarter of 2024

    Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million), and EBITDA of NOK 7.9 million (NOK -1.2 million) following positive operational developments and cost control. The Company reiterates its business and financial guidance for 2024 with 40 to 70 new and upgraded Saphira™ blue light tower installations during the year, product revenue growth of 6% to 9% in constant currency, and positive EBITDA excluding b